Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. <i>ASXL1/TET2</i> genotype-based risk stratification outperforms <i>ASXL1</i&gt; mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 2024;109(10):3419-3425; https://doi.org/10.3324/haematol.2024.285410.